We are live on ! Find out more
AXDX

Accelerate Diagnostics
AXDX

Delisted

AXDX was delisted on the 14th of May, 2025.

Back to rankings

84 hedge funds and large institutions have $41.2M invested in Accelerate Diagnostics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 8

121% more capital invested

Capital invested by funds: $18.6M → $41.2M (+$22.6M)

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

14% more funds holding

Funds holding: 74 → 84 (+10)

85% less call options, than puts

Call options by funds: $190K | Put options by funds: $1.23M

Holders
84
Holders Change
+10
Holders Change %
+13.51%
% of All Funds
1.45%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
19
Increased
16
Reduced
14
Closed
8
Calls
$190K
Puts
$1.23M
Net Calls
-$1.04M
Net Calls Change
-$228K

Top Buyers

Rank Fund Capital Flow
1
GAM
Griffin Asset Management
New York
+$5.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.88M
3
JP Morgan Chase
JP Morgan Chase
New York
+$1.77M
4
Millennium Management
Millennium Management
New York
+$1.19M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$862K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.88M
2
OIM
Oracle Investment Management
Connecticut
-$392K
3
CIA
Cladis Investment Advisory
Montana
-$137K
4
E
Ergoteles
New York
-$131K
5
HF
HRT Financial
New York
-$114K
Name Holding Trade Value Shares
Change 		Change in
Stake
GAM
1
Griffin Asset Management
New York
$11.1M +$5.5M +332,070 +83%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.29M +$862K +52,065 +23%
BC
3
Birchview Capital
Vermont
$3.42M – – –
OIM
4
Oracle Investment Management
Connecticut
$3.36M -$392K -23,692 -10%
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$2.64M +$2.88M +173,721 New
JP Morgan Chase
6
JP Morgan Chase
New York
$2.2M +$1.77M +106,928 +282%
CC
7
Cannell & Co
New York
$1.71M +$57.9K +3,500 +3%
Millennium Management
8
Millennium Management
New York
$1.45M +$1.19M +71,896 +302%
BlackRock
9
BlackRock
New York
$951K +$97.8K +5,909 +10%
CIA
10
Cladis Investment Advisory
Montana
$822K -$137K -8,300 -13%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$776K +$526K +31,755 +165%
AIC
12
AWM Investment Company
New York
$746K +$813K +49,110 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$703K +$235K +14,214 +44%
1CM
14
1492 Capital Management
Wisconsin
$684K +$744K +44,975 New
BAM
15
Belpointe Asset Management
Nevada
$529K -$99 -6 -0%
State Street
16
State Street
Massachusetts
$488K +$124K +7,470 +30%
DCM
17
Driehaus Capital Management
Illinois
$456K +$497K +30,000 New
DKCM
18
Davidson Kempner Capital Management
New York
$383K – – –
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$381K +$50.1K +3,028 +14%
EVM
20
Eaton Vance Management
Massachusetts
$339K – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$329K +$359K +21,674 New
Calamos Advisors
22
Calamos Advisors
Illinois
$266K +$289K +17,449 New
William Blair & Company
23
William Blair & Company
Illinois
$258K +$190K +11,460 +209%
AF
24
Allworth Financial
California
$234K – – –
Tudor Investment Corp
25
Tudor Investment Corp
Connecticut
$215K – – –
1
2 3 4

AXDX Hedge Fund Activity: Q3 2022 in Review

84 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2022, worth a combined $41.2M — up 121% from $18.6M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AXDX positions and 8 closed out — a net gain of 11 holders — while 16 added to existing stakes and 14 trimmed.

The largest buyer was Griffin Asset Management, adding an estimated $5.5M. The largest seller was Citadel Advisors, cutting an estimated $1.88M.

  • 84 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2022, up from 74 in Q2 2022.
  • Funds reported $41.2M of Accelerate Diagnostics stock for Q3 2022, up 121% quarter-over-quarter.
  • 19 funds opened new Accelerate Diagnostics positions in Q3 2022 and 8 closed out, a net change of +11 holders.
  • The largest Accelerate Diagnostics buyer in Q3 2022 was Griffin Asset Management, an estimated $5.5M added.
  • The largest Accelerate Diagnostics seller in Q3 2022 was Citadel Advisors, an estimated $1.88M sold.

Based on aggregated 13F filings for Q3 2022.